Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4208-4212

  Du, Wei ^a,b   Liu, Aixue ^a   Prendergast, George C ^a,b  

^a WISTAR INSTITUTE   (United States)

^b Glenolden Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTEGRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; RAT;

EID: 0033198386     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gibbs, J., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
2. Gibbs, J. B., and Oliff, A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol., 37: 143-166, 1997.
3. Leonard, D. M. Ras farnesyltransferase: a new therapeutic target. J. Med. Chem., 40: 2971-2990, 1997.
4. Sebti, S. M., and Hamilton, A. D Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther., 74: 103-114, 1997.
5. Cox, A. D., and Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta, 1333: F51-F71, 1997.
6. Du, W., Lebowitz, P., and Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol., 19: 1831-1840, 1999.
7. Lebowitz, P. F., and Prendergast, G. C. Non-Ras targets for farnesyltransferase inhibitors: focus on Rho. Oncogene, 17: 1439-1447, 1998.
8. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
9. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Marsters, J. C. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC), 260: 1937-1942, 1993.
10. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a famesyltransferase inhibitor. Science (Washington DC), 260: 1934-1937, 1993.
11. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
12. Kohl, N. E., Redner, F., Mosser, S., Guiliani, E. A., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T-J., Smith, R. L., Graham, S. L., Hartman, G. D., Gibbs, J., and Oliff, A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
13. Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lu, S., Malumbres, M., Gibbs, J. B., Oliff, A., and Pellicer, A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res., 58: 1253-1259, 1998.
14. Manne, V., Van, N., Carboni, J. M., Tuomari, A. V., Ricca, C. S., Brown, J. G., Andahazy, M. L., Schmidt, R. J., Patel, D., Zahler, R., Weinmann, R., Der, C. J., Cox, A. D., Hunt, J. T., Gordon, E. M., Barbacid, M., and Seizinger, B. R. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras-transformed cells. Oncogene, 10: 1763-1779, 1995.
15. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
16. Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E., Graham, S., Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol., 14: 4193-4202, 1994.
17. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
18. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
19. Lebowitz, P. F., Sakamuro, D., and Prendergast, G. C. Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment. Cancer Res., 57: 708-713, 1997.
20. Datta, K., Bellacosa, A., Chan, T. O., and Tsichlis, P. N. Akt is a direct target of the phosphatidylinositol 3-kinase: activation by growth factors, v-src, and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem., 271: 30835-30839, 1996.
21. Chen, Y., Meyer, F. C., and Tan, T. Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in radiation-induced apoptosis. J. Biol. Chem., 271: 631-634, 1996.
22. Harlow, E., and Lane, D. Antibodies. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1988.
23. Kumar, C. C. Signaling by integrin receptors. Oncogene, 17: 1365-1373, 1998.
24. O'Connor, R. Survival factors and apoptosis. Adv. Biochem. Eng. Biotechnol., 62: 137-166, 1998.
25. Franke, T. F., Kaplan, D. R., and Cantley, L. C. P13K: downstream AKTion blocks apoptosis. Cell, 88: 435-437, 1997.
26. Frisch, S. M., and Ruoslahti, E. Integrins and anoikis. Curr. Opin. Cell Biol., 9: 701-706, 1997.
27. Marte, B. M., and Downward, J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci., 22: 355-358, 1997.
28. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (Washington DC), 275: 661-665, 1997.
29. Prendergast, G. C., Davide, J. P., Lebowitz, P. F., Wechsler-Reya, R., and Kohl, N. E. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res., 56: 2626-2632, 1996.
30. Suzuki, N., Urano, J., and Tamanoi, F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc. Natl. Acad. Sci. USA, 95: 15356-15361, 1998.
31. Perona, R., Montaner, S., Saniger, L., Sanchez-Perez, I., Bravo, R., and Lacal, J. C. Activation of the nuclear factor-κB by Rho, CDC42, and Rac-1 proteins. Genes Dev., 11: 463-475, 1997.
32. Mayo, M. W., Wang, C. Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., and Baldwin, A. S. J. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (Washington DC), 278: 1812-1815, 1997.
33. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science (Washington DC), 282: 1318-1321, 1998.
34. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
35. Rosen, K., Rak, J., Jin, J., Kerbel, R. S., Newman, M. J., and Filmus, J. Down-regulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells. Curr. Biol., 8: 1331-1334, 1998.
36. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M., Ferrari, E., Nielsen, L., Prioli, N., Dell, J., Sinha, D., Syed, J., Dorfmacher, W. A., Nomeir, A. A., Lin, C-C., Wang, L., Taveras, A. G., Doll, R. J., Njoroge, F. G., Mallams, A. K., Remiszewski, S., Catino, J. J., Girijavallabhan, V. M., Kirschmeier, P., and Bishop, W. R. Antitumor activity of SCH 6636, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res., 58: 4947-4956, 1998.
37. Olson, M. F., Paterson, H. F., and Marshall, C. J. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature (Lond.), 394: 295-299, 1998.
38. Balendran, A., Casamayor, A., Deak, M., Paterson, A., Gaffney, P., Currie, R., Downes, C. P., and Alessi, D. R. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr. Biol., 9: 393-404, 1999.